With apologies for any inconvenience, we are currently experiencing some technical difficulties. Please bear with us.
This bulletin compares goserelin, leuprorelin and triptorelin for the treatment of prostate cancer.
Medicine optimisation projects, including switching therapy to cost-effective alternatives which are more convenient for patients, are outlined and implementation tools provided.
Please login to view this content
